Welcome to our dedicated page for Surrozen SEC filings (Ticker: SRZNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Surrozen, Inc. (SRZNW for its warrants and SRZN for its common stock) files reports and disclosure documents with the U.S. Securities and Exchange Commission as a public biotechnology company in the biological product manufacturing industry. This SEC filings page brings together those documents so users can review how Surrozen describes its business, capital structure, and material events in official regulatory submissions.
Surrozen’s filings include Form 8-K current reports that outline significant corporate developments. For example, one Form 8-K describes a Sales Agreement with TD Securities (USA) LLC (TD Cowen) that allows Surrozen to offer and sell shares of its common stock in at-the-market offerings under a Form S-3 registration statement. The filing explains that TD Cowen may sell shares on the Nasdaq Capital Market or other existing trading markets, and that Surrozen will pay a commission on gross sales proceeds and provide customary indemnification.
Another Form 8-K details the issuance of a press release announcing Surrozen’s financial results for a specific quarter, categorized under "Results of Operations and Financial Condition." In that report, the company notes that the information, including the press release exhibit, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Such filings help readers understand how Surrozen reports its operating performance and significant events.
On this page, users can access Surrozen’s SEC filings as they are made available through EDGAR, including current reports like Form 8-K, registration statements such as Form S-3, and related exhibits. AI-powered summaries can assist in interpreting key sections, such as descriptions of capital-raising arrangements, warrant and common stock references, and other disclosures about Surrozen’s Wnt pathway-focused biotechnology business.
Driehaus Capital Management LLC reports beneficial ownership of 67,566 shares of Surrozen, Inc. common stock, equal to 0.79% of the class. The filing shows Driehaus has shared voting and shared dispositive power over all 67,566 shares and reports no sole voting or dispositive power. The filer is identified as an investment adviser (IA). Item 5 is marked for ownership of 5 percent or less of a class, and Items 6-9 indicate no holdings on behalf of others, no parent/subsidiary acquisition, and no group affiliation.
Surrozen, Inc. is the issuer and this Schedule 13G/A discloses that Stonepine-related reporting persons collectively beneficially own 508,687 shares of Surrozen common stock, representing 5.8% of the outstanding class. That total is composed of 306,029 shares of Common Stock plus 202,658 shares issuable on exercise of Series A, B and E warrants, with the calculation based on 8,570,355 shares outstanding as reported by the issuer.
The reporting persons (Stonepine Capital Management, LLC; Stonepine Capital, L.P.; Stonepine GP, LLC; and Jon M. Plexico) report shared voting and dispositive power over the 508,687 shares and no sole voting or dispositive power. The partnership holds the shares for investors and may direct receipt of dividends or sale proceeds. The filing includes a certification that the position was not acquired to change or influence control of the issuer.
Surrozen, Inc. registers 250,000 shares of its common stock, par value $0.0001 per share, to be issued under the Surrozen, Inc. 2025 Equity Inducement Plan. The registration statement incorporates the company’s prior annual, proxy, quarterly and current reports by reference so that those documents form part of the disclosure for the plan.
The filing reiterates that the company provides contractual indemnification to directors and officers under Delaware law, maintains indemnification agreements and standard directors-and-officers insurance, and includes the 2025 Plan and related legal and auditor consents as exhibits.
Surrozen reported a cash position of $90.4 million and returned a net income of $39.7 million for the three months ended June 30, 2025, and $12.8 million for the six‑month period, driven largely by noncash fair‑value changes in a tranche liability and warrant liabilities. Operating activities used $15.4 million of cash in the first half of 2025 while the company recorded a consolidated accumulated deficit of approximately $272.5 million. In March 2025 Surrozen completed the first tranche of a two‑tranche private placement (the 2025 PIPE), raising net proceeds of about $71.2 million from the first closing and issuing 5.2 million shares, pre‑funded warrants and Series E warrants; the second tranche is contingent on FDA clearance of an IND for SZN‑8141. Warrant liabilities and a remaining tranche liability create significant noncash volatility: warrant liabilities were reported at $32.6 million and the tranche liability at $10.9 million as of June 30, 2025. Management believes existing cash is sufficient for at least 12 months, but the company expects continued R&D spending and may need additional capital to advance its pipeline.
Surrozen, Inc. reported by way of a Current Report on Form 8-K that on August 8, 2025 it issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to the 8-K as Exhibit 99.1 and the filing also includes the Cover Page Interactive Data File (Exhibit 104). The company notes that the information in Item 2.02 and the attached exhibit is not deemed to be "filed" for Section 18 purposes and will not be incorporated by reference into other filings under the Securities Act.
The report lists the company as an emerging growth company and confirms securities registered on Nasdaq: Common Stock (SRZN) and Redeemable warrants (SRZNW). The document is signed by Charles Williams, Chief Financial Officer, Chief Operating Officer and Corporate Secretary.